Summary
Global Markets Direct’s, ‘Dyslipidemia - Pipeline Review, H1 2016’, provides an overview of the Dyslipidemia pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Dyslipidemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Dyslipidemia
- The report reviews pipeline therapeutics for Dyslipidemia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Dyslipidemia therapeutics and enlists all their major and minor projects
- The report assesses Dyslipidemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Dyslipidemia
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Dyslipidemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Dyslipidemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Acasti Pharma Inc.
Allergan Plc
Alnylam Pharmaceuticals, Inc.
Amgen Inc.
Arbutus Biopharma Corporation
Arisaph Pharmaceuticals, Inc.
Astellas Pharma Inc.
AstraZeneca Plc
AtheroNova Inc.
BASF SE
BCWorld Pharm Co. Ltd.
Cadila Pharmaceuticals Ltd.
Cardax Pharmaceuticals, Inc.
Catabasis Pharmaceuticals, Inc.
Cerenis Therapeutics Holding SA
Chong Kun Dang Pharmaceutical Corp.
CJ HealthCare Corp.
Connexios Life Sciences Pvt. Ltd.
CymaBay Therapeutics, Inc.
Daewoong Pharmaceutical Co., Ltd.
Daiichi Sankyo Company, Limited
Debiopharm International S.A.
Eli Lilly and Company
Esperion Therapeutics, Inc.
Genfit SA
GlaxoSmithKline Plc
HanAll Biopharma Co., Ltd.
Hanmi Pharmaceuticals, Co. Ltd.
Huons Co., Ltd.
Hyundai Pharmaceutical Co., Ltd.
Innovent Biologics, Inc.
IPCA Laboratories Limited
Jeil Pharmaceutical Co., Ltd.
Jenrin Discovery, Inc.
JW Pharmaceutical Corporation
Kissei Pharmaceutical Co., Ltd.
Kotobuki Pharmaceutical Co., Ltd.
Kowa Company, Ltd.
Kymab Limited
LG Life Science LTD.
Lipicard Technologies Limited
Lotus Pharmaceutical Co., Ltd.
Matinas BioPharma Holdings, Inc.
Merck & Co., Inc.
Nimbus Therapeutics, LLC
Nippon Chemiphar Co., Ltd.
Pfizer Inc.
Pharmena SA
Prometheon Pharma, LLC
Protalix BioTherapeutics, Inc.
Regeneron Pharmaceuticals, Inc.
Sancilio & Company, Inc.
Takeda Pharmaceutical Company Limited
Thetis Pharmaceuticals LLC
Torrent Pharmaceuticals Limited
Viking Therapeutics, Inc.
Yuhan Corporation
Zydus Cadila Healthcare Limited
'
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Dyslipidemia Overview 12
Therapeutics Development 13
Pipeline Products for Dyslipidemia - Overview 13
Pipeline Products for Dyslipidemia - Comparative Analysis 14
Dyslipidemia - Therapeutics under Development by Companies 15
Dyslipidemia - Therapeutics under Investigation by Universities/Institutes 21
Dyslipidemia - Pipeline Products Glance 22
Late Stage Products 22
Clinical Stage Products 23
Early Stage Products 24
Unknown Stage Products 25
Dyslipidemia - Products under Development by Companies 26
Dyslipidemia - Products under Investigation by Universities/Institutes 34
Dyslipidemia - Companies Involved in Therapeutics Development 35
Acasti Pharma Inc. 35
Allergan Plc 36
Alnylam Pharmaceuticals, Inc. 37
Amgen Inc. 38
Arbutus Biopharma Corporation 39
Arisaph Pharmaceuticals, Inc. 40
Astellas Pharma Inc. 41
AstraZeneca Plc 42
AtheroNova Inc. 43
BASF SE 44
BCWorld Pharm Co. Ltd. 45
Cadila Pharmaceuticals Ltd. 46
Cardax Pharmaceuticals, Inc. 47
Catabasis Pharmaceuticals, Inc. 48
Cerenis Therapeutics Holding SA 49
Chong Kun Dang Pharmaceutical Corp. 50
CJ HealthCare Corp. 51
Connexios Life Sciences Pvt. Ltd. 52
CymaBay Therapeutics, Inc. 53
Daewoong Pharmaceutical Co., Ltd. 54
Daiichi Sankyo Company, Limited 55
Debiopharm International S.A. 56
Eli Lilly and Company 57
Esperion Therapeutics, Inc. 58
Genfit SA 59
GlaxoSmithKline Plc 60
HanAll Biopharma Co., Ltd. 61
Hanmi Pharmaceuticals, Co. Ltd. 62
Huons Co., Ltd. 63
Hyundai Pharmaceutical Co., Ltd. 64
Innovent Biologics, Inc. 65
IPCA Laboratories Limited 66
Jeil Pharmaceutical Co., Ltd. 67
Jenrin Discovery, Inc. 68
JW Pharmaceutical Corporation 69
Kissei Pharmaceutical Co., Ltd. 70
Kotobuki Pharmaceutical Co., Ltd. 71
Kowa Company, Ltd. 72
Kymab Limited 73
LG Life Science LTD. 74
Lipicard Technologies Limited 75
Lotus Pharmaceutical Co., Ltd. 76
Matinas BioPharma Holdings, Inc. 77
Merck & Co., Inc. 78
Nimbus Therapeutics, LLC 79
Nippon Chemiphar Co., Ltd. 80
Pfizer Inc. 81
Pharmena SA 82
Prometheon Pharma, LLC 83
Protalix BioTherapeutics, Inc. 84
Regeneron Pharmaceuticals, Inc. 85
Sancilio & Company, Inc. 86
Takeda Pharmaceutical Company Limited 87
Thetis Pharmaceuticals LLC 88
Torrent Pharmaceuticals Limited 89
Viking Therapeutics, Inc. 90
Yuhan Corporation 91
Zydus Cadila Healthcare Limited 92
Dyslipidemia - Therapeutics Assessment 93
Assessment by Monotherapy Products 93
Assessment by Combination Products 94
Assessment by Target 95
Assessment by Mechanism of Action 100
Assessment by Route of Administration 103
Assessment by Molecule Type 105
Drug Profiles 107
(amlodipine besylate + atorvastatin calcium + valsartan) - Drug Profile 107
(amlodipine besylate + rosuvastatin calcium + valsartan) - Drug Profile 108
(atorvastatin calcium + choline fenofibrate) - Drug Profile 109
(atorvastatin calcium + hydroxychloroquine sulfate) - Drug Profile 110
(atorvastatin calcium + losartan potassium) - Drug Profile 111
(atorvastatin calcium + metformin hydrochloride) XR - Drug Profile 112
(candesartan + rosuvastatin calcium) - Drug Profile 113
(ezetimibe + rosuvastatin calcium) - Drug Profile 114
(gemigliptin + rosuvastatin calcium) - Drug Profile 115
(metformin hydrochloride SR + rosuvastatin calcium) - Drug Profile 116
(pitavastatin + valsartan) - Drug Profile 117
4655-K09 - Drug Profile 118
AEM-28 - Drug Profile 119
AEM-2802 - Drug Profile 120
AEM-2814 - Drug Profile 121
AHRO-001 - Drug Profile 122
ALN-AC3 - Drug Profile 124
ALN-ANG - Drug Profile 125
AMG-899 - Drug Profile 126
anacetrapib - Drug Profile 127
ARI-3037MO - Drug Profile 129
AS-1708727 - Drug Profile 130
AZ-12260493 - Drug Profile 131
BCWPC-001 - Drug Profile 132
bempedoic acid - Drug Profile 133
bezafibrate ER - Drug Profile 136
BH-03004 - Drug Profile 137
BioE-1115 - Drug Profile 138
bococizumab - Drug Profile 139
BSN-272 - Drug Profile 140
C-24 - Drug Profile 141
C-3 - Drug Profile 142
CAT-2000 Series - Drug Profile 143
CAT-2003 - Drug Profile 144
CDR-267F018 - Drug Profile 145
CDX-085 - Drug Profile 146
centatin - Drug Profile 148
CER-209 - Drug Profile 149
CKD-519 - Drug Profile 150
CNX-013B2 - Drug Profile 151
Debio-0930B - Drug Profile 152
DF-461 - Drug Profile 153
DPR-212 - Drug Profile 154
DS-8312 - Drug Profile 155
DS-9001 - Drug Profile 156
DWJ-1330 - Drug Profile 158
DWJ-1351 - Drug Profile 159
elafibranor - Drug Profile 160
etanercept biosimilar - Drug Profile 163
evinacumab - Drug Profile 164
evolocumab - Drug Profile 165
gemcabene calcium - Drug Profile 168
GSK-2041706 - Drug Profile 169
HCP-1105 - Drug Profile 170
HOB-071 - Drug Profile 171
HU-012 - Drug Profile 172
IBI-306 - Drug Profile 173
icosabutate - Drug Profile 174
IONIS-ANGPTL3LRx - Drug Profile 175
ISIS-APOCIIILRx - Drug Profile 176
JD-2000 Series - Drug Profile 177
JD-5000 Series - Drug Profile 178
JD-5006 - Drug Profile 179
JD-5037 - Drug Profile 180
JD-6000 Series - Drug Profile 181
JLP-1302 - Drug Profile 182
JLP-1401 - Drug Profile 183
K-312 - Drug Profile 184
K-877 - Drug Profile 185
KT-6971 - Drug Profile 187
KTA-439 - Drug Profile 188
KY-1020 - Drug Profile 189
leucine + niacin - Drug Profile 190
LP-071 - Drug Profile 191
LT-5421 - Drug Profile 192
LT-5423 - Drug Profile 193
MAT-9001 - Drug Profile 194
MBX-8025 - Drug Profile 195
NC-2400 - Drug Profile 197
ND-630 - Drug Profile 198
ND-654 - Drug Profile 199
NKPL-66 - Drug Profile 201
Oligonucleotide for Hyperlipidemia and Atherosclerosis - Drug Profile 203
omega-3-carboxylic acids - Drug Profile 204
peroxibrate - Drug Profile 206
PF-06427878 - Drug Profile 207
PF-06815345 - Drug Profile 208
pitavastatin CR - Drug Profile 209
Protein to Inhibit HMG-CoA Reductase for Hyperlipidemia - Drug Profile 210
Recombinant ApoE4 for Dyslipidemia - Drug Profile 211
REGN-1001 - Drug Profile 212
saroglitazar - Drug Profile 213
SC-401 - Drug Profile 214
Small Molecule 1 to Inhibit Diacylglycerol Acyltransferase for Obesity, Dyslipidemia and Type-2 diabetes - Drug Profile 215
Small Molecule 2 to Inhibit Diacylglycerol Acyltransferase for Obesity, Dyslipidemia and Type-2 diabetes - Drug Profile 216
Small Molecule for Hyperlipidemia - Drug Profile 217
Small Molecule for Hypertriglyceridaemia - Drug Profile 218
Small Molecule for Hypertriglyceridemia - Drug Profile 219
Small Molecule for Type-2 diabetes and Hyperlipidemia - Drug Profile 220
Small Molecule to Activate Lipoprotein Lipase for Dyslipidemia - Drug Profile 221
Small Molecule to Activate Lipoprotein Lipase for Dyslipidemia - Drug Profile 222
Small Molecule to Agonize TR-Beta for Dyslipidemia - Drug Profile 223
Small Molecule to Antagonize Farnesoid X Receptor for Dyslipidemia - Drug Profile 224
Small Molecule to Inhibit TRIP-Br2 for Metabolic Disorders - Drug Profile 225
Small Molecules for Dyslipidemia and Hypertriglyceridemia - Drug Profile 226
Small Molecules to Inhibit DGAT-1 for Dyslipidemia and Obesity - Drug Profile 227
Small Molecules to Inhibit Endothelial Lipase for Dyslipidemia - Drug Profile 228
SPX-100 - Drug Profile 229
SPX-8522876 - Drug Profile 230
Synthetic Peptides for Cardiovascular, Gastrointestinal, Metabolic Disorders and Infectious Disease - Drug Profile 231
TKMApoC-3 - Drug Profile 233
TP-101 - Drug Profile 234
TP-452 - Drug Profile 235
TRC-210258 - Drug Profile 236
TRIA-662 - Drug Profile 237
VK-0214 - Drug Profile 239
VK-2809 - Drug Profile 240
volanesorsen sodium - Drug Profile 242
YH-22189 - Drug Profile 244
ZLN-005 - Drug Profile 245
ZLN-024 - Drug Profile 246
ZYH-7 - Drug Profile 247
Dyslipidemia - Recent Pipeline Updates 248
Dyslipidemia - Dormant Projects 306
Dyslipidemia - Discontinued Products 322
Dyslipidemia - Product Development Milestones 328
Featured News & Press Releases 328
Appendix 336
Methodology 336
Coverage 336
Secondary Research 336
Primary Research 336
Expert Panel Validation 336
Contact Us 336
Disclaimer 337
List of Tables
Number of Products under Development for Dyslipidemia, H1 2016 21
Number of Products under Development for Dyslipidemia - Comparative Analysis, H1 2016 22
Number of Products under Development by Companies, H1 2016 24
Number of Products under Development by Companies, H1 2016 (Contd..1) 25
Number of Products under Development by Companies, H1 2016 (Contd..2) 26
Number of Products under Development by Companies, H1 2016 (Contd..3) 27
Number of Products under Development by Companies, H1 2016 (Contd..4) 28
Number of Products under Investigation by Universities/Institutes, H1 2016 29
Comparative Analysis by Late Stage Development, H1 2016 30
Comparative Analysis by Clinical Stage Development, H1 2016 31
Comparative Analysis by Early Stage Development, H1 2016 32
Comparative Analysis by Unknown Stage Development, H1 2016 33
Products under Development by Companies, H1 2016 34
Products under Development by Companies, H1 2016 (Contd..1) 35
Products under Development by Companies, H1 2016 (Contd..2) 36
Products under Development by Companies, H1 2016 (Contd..3) 37
Products under Development by Companies, H1 2016 (Contd..4) 38
Products under Development by Companies, H1 2016 (Contd..5) 39
Products under Development by Companies, H1 2016 (Contd..6) 40
Products under Development by Companies, H1 2016 (Contd..7) 41
Products under Investigation by Universities/Institutes, H1 2016 42
Dyslipidemia - Pipeline by Acasti Pharma Inc., H1 2016 43
Dyslipidemia - Pipeline by Allergan Plc, H1 2016 44
Dyslipidemia - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016 45
Dyslipidemia - Pipeline by Amgen Inc., H1 2016 46
Dyslipidemia - Pipeline by Arbutus Biopharma Corporation, H1 2016 47
Dyslipidemia - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2016 48
Dyslipidemia - Pipeline by Astellas Pharma Inc., H1 2016 49
Dyslipidemia - Pipeline by AstraZeneca Plc, H1 2016 50
Dyslipidemia - Pipeline by AtheroNova Inc., H1 2016 51
Dyslipidemia - Pipeline by BASF SE, H1 2016 52
Dyslipidemia - Pipeline by BCWorld Pharm Co. Ltd., H1 2016 53
Dyslipidemia - Pipeline by Cadila Pharmaceuticals Ltd., H1 2016 54
Dyslipidemia - Pipeline by Cardax Pharmaceuticals, Inc., H1 2016 55
Dyslipidemia - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2016 56
Dyslipidemia - Pipeline by Cerenis Therapeutics Holding SA, H1 2016 57
Dyslipidemia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 58
Dyslipidemia - Pipeline by CJ HealthCare Corp., H1 2016 59
Dyslipidemia - Pipeline by Connexios Life Sciences Pvt. Ltd., H1 2016 60
Dyslipidemia - Pipeline by CymaBay Therapeutics, Inc., H1 2016 61
Dyslipidemia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016 62
Dyslipidemia - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 63
Dyslipidemia - Pipeline by Debiopharm International S.A., H1 2016 64
Dyslipidemia - Pipeline by Eli Lilly and Company, H1 2016 65
Dyslipidemia - Pipeline by Esperion Therapeutics, Inc., H1 2016 66
Dyslipidemia - Pipeline by Genfit SA, H1 2016 67
Dyslipidemia - Pipeline by GlaxoSmithKline Plc, H1 2016 68
Dyslipidemia - Pipeline by HanAll Biopharma Co., Ltd., H1 2016 69
Dyslipidemia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 70
Dyslipidemia - Pipeline by Huons Co., Ltd., H1 2016 71
Dyslipidemia - Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2016 72
Dyslipidemia - Pipeline by Innovent Biologics, Inc., H1 2016 73
Dyslipidemia - Pipeline by IPCA Laboratories Limited, H1 2016 74
Dyslipidemia - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2016 75
Dyslipidemia - Pipeline by Jenrin Discovery, Inc., H1 2016 76
Dyslipidemia - Pipeline by JW Pharmaceutical Corporation, H1 2016 77
Dyslipidemia - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2016 78
Dyslipidemia - Pipeline by Kotobuki Pharmaceutical Co., Ltd., H1 2016 79
Dyslipidemia - Pipeline by Kowa Company, Ltd., H1 2016 80
Dyslipidemia - Pipeline by Kymab Limited, H1 2016 81
Dyslipidemia - Pipeline by LG Life Science LTD., H1 2016 82
Dyslipidemia - Pipeline by Lipicard Technologies Limited, H1 2016 83
Dyslipidemia - Pipeline by Lotus Pharmaceutical Co., Ltd., H1 2016 84
Dyslipidemia - Pipeline by Matinas BioPharma Holdings, Inc. , H1 2016 85
Dyslipidemia - Pipeline by Merck & Co., Inc., H1 2016 86
Dyslipidemia - Pipeline by Nimbus Therapeutics, LLC, H1 2016 87
Dyslipidemia - Pipeline by Nippon Chemiphar Co., Ltd., H1 2016 88
Dyslipidemia - Pipeline by Pfizer Inc., H1 2016 89
Dyslipidemia - Pipeline by Pharmena SA, H1 2016 90
Dyslipidemia - Pipeline by Prometheon Pharma, LLC, H1 2016 91
Dyslipidemia - Pipeline by Protalix BioTherapeutics, Inc., H1 2016 92
Dyslipidemia - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 93
Dyslipidemia - Pipeline by Sancilio & Company, Inc., H1 2016 94
Dyslipidemia - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 95
Dyslipidemia - Pipeline by Thetis Pharmaceuticals LLC, H1 2016 96
Dyslipidemia - Pipeline by Torrent Pharmaceuticals Limited, H1 2016 97
Dyslipidemia - Pipeline by Viking Therapeutics, Inc., H1 2016 98
Dyslipidemia - Pipeline by Yuhan Corporation, H1 2016 99
Dyslipidemia - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 100
Assessment by Monotherapy Products, H1 2016 101
Assessment by Combination Products, H1 2016 102
Number of Products by Stage and Target, H1 2016 104
Number of Products by Stage and Mechanism of Action, H1 2016 109
Number of Products by Stage and Route of Administration, H1 2016 112
Number of Products by Stage and Molecule Type, H1 2016 114
Dyslipidemia Therapeutics - Recent Pipeline Updates, H1 2016 256
Dyslipidemia - Dormant Projects, H1 2016 314
Dyslipidemia - Dormant Projects (Contd..1), H1 2016 315
Dyslipidemia - Dormant Projects (Contd..2), H1 2016 316
Dyslipidemia - Dormant Projects (Contd..3), H1 2016 317
Dyslipidemia - Dormant Projects (Contd..4), H1 2016 318
Dyslipidemia - Dormant Projects (Contd..5), H1 2016 319
Dyslipidemia - Dormant Projects (Contd..6), H1 2016 320
Dyslipidemia - Dormant Projects (Contd..7), H1 2016 321
Dyslipidemia - Dormant Projects (Contd..8), H1 2016 322
Dyslipidemia - Dormant Projects (Contd..9), H1 2016 323
Dyslipidemia - Dormant Projects (Contd..10), H1 2016 324
Dyslipidemia - Dormant Projects (Contd..11), H1 2016 325
Dyslipidemia - Dormant Projects (Contd..12), H1 2016 326
Dyslipidemia - Dormant Projects (Contd..13), H1 2016 327
Dyslipidemia - Dormant Projects (Contd..14), H1 2016 328
Dyslipidemia - Dormant Projects (Contd..15), H1 2016 329
Dyslipidemia - Discontinued Products, H1 2016 330
Dyslipidemia - Discontinued Products (Contd..1), H1 2016 331
Dyslipidemia - Discontinued Products (Contd..2), H1 2016 332
Dyslipidemia - Discontinued Products (Contd..3), H1 2016 333
Dyslipidemia - Discontinued Products (Contd..4), H1 2016 334
Dyslipidemia - Discontinued Products (Contd..5), H1 2016 335
List of Figures
Number of Products under Development for Dyslipidemia, H1 2016 21
Number of Products under Development for Dyslipidemia - Comparative Analysis, H1 2016 22
Number of Products under Development by Companies, H1 2016 23
Number of Products under Investigation by Universities/Institutes, H1 2016 29
Comparative Analysis by Late Stage Development, H1 2016 30
Comparative Analysis by Clinical Stage Development, H1 2016 31
Comparative Analysis by Early Stage Products, H1 2016 32
Assessment by Monotherapy Products, H1 2016 101
Assessment by Combination Products, H1 2016 102
Number of Products by Top 10 Targets, H1 2016 103
Number of Products by Stage and Top 10 Targets, H1 2016 103
Number of Products by Top 10 Mechanism of Actions, H1 2016 108
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 108
Number of Products by Routes of Administration, H1 2016 111
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 111
Number of Products by Molecule Types, H1 2016 113
Number of Products by Stage and Molecule Types, H1 2016 113
